These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 1853824)

  • 41. Acute effects of synthetic surfactant replacement on pulmonary blood flow in neonatal respiratory distress syndrome.
    Seppänen M; Kääpä P; Kero P
    Am J Perinatol; 1994 Nov; 11(6):382-5. PubMed ID: 7857426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Natural and synthetic surfactant in the treatment of neonatal respiratory distress syndrome].
    Bratlid D; Farstad T
    Tidsskr Nor Laegeforen; 1994 Jan; 114(1):33-6. PubMed ID: 8296279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials.
    Zhang L; Cao HY; Zhao S; Yuan LJ; Han D; Jiang H; Wu S; Wu HM
    Pulm Pharmacol Ther; 2015 Oct; 34():46-54. PubMed ID: 26296793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serial phospholipid analysis in preterm infants: comparison of Exosurf and Survanta.
    Lloyd J; Todd DA; John E
    Early Hum Dev; 1999 Mar; 54(2):157-68. PubMed ID: 10213294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo. American Exosurf Neonatal Study Group I.
    Sell M; Cotton R; Hirata T; Guthrie R; LeBlanc M; Mammel M; Long W
    J Pediatr; 1995 May; 126(5 Pt 2):S20-5. PubMed ID: 7745507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Respiratory distress syndrome treated with human surfactant: radiographic findings.
    Edwards DK; Hilton SV; Merritt TA; Hallman M; Mannino F; Boynton BR
    Radiology; 1985 Nov; 157(2):329-34. PubMed ID: 3840268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of two rescue doses of synthetic surfactant in 344 infants with respiratory distress syndrome weighing 750 to 1249 grams: a double-blind, placebo-controlled multicenter Canadian trial. Canadian Exosurf Neonatal Study Group.
    McMillan D; Chernick V; Finer N; Schiff D; Bard H; Watts J; Krzeski R; Long W
    J Pediatr; 1995 May; 126(5 Pt 2):S90-8. PubMed ID: 7745517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant.
    Abbasi S; Bhutani VK; Gerdes JS
    J Pediatr; 1993 Mar; 122(3):446-52. PubMed ID: 8441104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebral blood flow velocity after surfactant instillation in preterm infants.
    van de Bor M; Ma EJ; Walther FJ
    J Pediatr; 1991 Feb; 118(2):285-7. PubMed ID: 1993962
    [No Abstract]   [Full Text] [Related]  

  • 50. Exosurf treatment investigational new drug phase: effect of an individualized third dose in infants with respiratory distress syndrome.
    Easa D; Pelke S; Nakamura KT; Barrett J; Balaraman V; Loo SW; Ibarra-Pratt E; Smith MB
    Pediatr Pulmonol; 1992 Sep; 14(1):16-22. PubMed ID: 1437338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exogenous surfactant use in neonates.
    Ishisaka DY
    Ann Pharmacother; 1996 Apr; 30(4):389-98. PubMed ID: 8729894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs.
    Cummings JJ; Holm BA; Hudak ML; Hudak BB; Ferguson WH; Egan EA
    Am Rev Respir Dis; 1992 May; 145(5):999-1004. PubMed ID: 1586078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of clinical responses to natural and synthetic surfactants.
    Rollins M; Jenkins J; Tubman R; Corkey C; Wilson D
    J Perinat Med; 1993; 21(5):341-7. PubMed ID: 8126629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surfactant replacement therapy: issues related to currently available preparations.
    Bose G
    Neonatal Netw; 1992 Jun; 11(4):vii-xii. PubMed ID: 1608367
    [No Abstract]   [Full Text] [Related]  

  • 55. Costs and outcomes associated with colfosceril versus beractant for the treatment of neonatal respiratory distress syndrome.
    Wyble L; Santeiro ML
    Ann Pharmacother; 1997 Jun; 31(6):787-8. PubMed ID: 9184726
    [No Abstract]   [Full Text] [Related]  

  • 56. Surfactant respiratory therapy using Surfaxin/sinapultide.
    Lal MK; Sinha SK
    Ther Adv Respir Dis; 2008 Oct; 2(5):339-44. PubMed ID: 19124381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Systemic and pulmonary hemodynamics in the course of substitute therapy with exosurf neonatal in newborn infants with respiratory distress syndrome].
    Milenin OB; Efimov MS
    Anesteziol Reanimatol; 1996; (6):7-10. PubMed ID: 9045592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of surfactant therapy in infants managed with CPAP.
    Alba J; Agarwal R; Hegyi T; Hiatt IM
    Pediatr Pulmonol; 1995 Sep; 20(3):172-6. PubMed ID: 8545169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Partial liquid ventilation in premature lambs with respiratory distress syndrome: efficacy and compatibility with exogenous surfactant.
    Leach CL; Holm B; Morin FC; Fuhrman BP; Papo MC; Steinhorn D; Hernan LJ
    J Pediatr; 1995 Mar; 126(3):412-20. PubMed ID: 7869204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exosurf rescue surfactant improves high ventilation-perfusion mismatch in respiratory distress syndrome.
    Billman D; Nicks J; Schumacher R
    Pediatr Pulmonol; 1994 Nov; 18(5):279-83. PubMed ID: 7898965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.